Company intelligence / Profile preview

Link Medicine Corporation

Massachusetts, USApmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Link Medicine developed small molecule assets targeting the enzyme farnesyltransferase to modulate autophagy for neurodegenerative diseases. The company was acquired by AstraZeneca in July 2012, which took over all research and development activities.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

AstraZeneca

Beyond the preview

Go deeper on Link Medicine Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Link Medicine Corporation.

Explore the full profile